Rein Therapeutics (NASDAQ:RNTX) Insider James Brian Windsor Buys 25,000 Shares

Rein Therapeutics Inc. (NASDAQ:RNTX) insider James Brian Windsor acquired 25,000 shares of the company’s stock in a transaction on Thursday, April 30th. The stock was acquired at an average cost of $1.00 per share, with a total value of $25,000.00. Following the completion of the purchase, the insider directly owned 27,046 shares in the company, valued at approximately $27,046. This represents a 1,221.90% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Rein Therapeutics Stock Down 2.6%

Rein Therapeutics stock opened at $1.12 on Wednesday. The company’s 50-day moving average price is $1.38 and its 200-day moving average price is $1.34. The company has a market cap of $31.40 million, a PE ratio of -0.57 and a beta of 1.42. Rein Therapeutics Inc. has a twelve month low of $1.00 and a twelve month high of $2.40.

Institutional Investors Weigh In On Rein Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Chicago Partners Investment Group LLC lifted its stake in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares during the last quarter. Gagnon Securities LLC grew its position in Rein Therapeutics by 5.0% in the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after acquiring an additional 11,528 shares during the last quarter. Susquehanna International Group LLP purchased a new stake in Rein Therapeutics in the third quarter worth $35,000. HRT Financial LP purchased a new stake in Rein Therapeutics in the fourth quarter worth $38,000. Finally, Geode Capital Management LLC lifted its position in shares of Rein Therapeutics by 15.1% during the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock worth $330,000 after purchasing an additional 37,244 shares during the last quarter. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RNTX shares. Citigroup lowered Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Finally, lowered Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Rein Therapeutics has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.